Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensi
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. Thes
| Condition(s) | Cancer, Pancreatic Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment. |
| Who can participate | Inclusion Criteria: * Histological and/or radiological diagnosis of metastatic PDAC. Patients without a histological diagnosis of PDAC must undergo confirmatory tumour biopsy prior to treatment start date. * Planned for first-line systemic therapy with FOLFIRINOX or GP, either in routine care or in combination with an investigational agent(s) within a clinical trial. * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate organ function * Life expectancy of \> 90 days as judged by the investigator * Ability to give informed consent * Measurable disease by RECIST 1.1 * Presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist. A minimum of 3 tumour cores must be safely obtainable under CT or US guidance. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | British Columbia Cancer Agency |
| Locations | Calgary, Alberta, Canada; Edmonton, Alberta, Canada; Vancouver, British Columbia, Canada; Ottawa, Ontario, Canada |
| Start date | 2016-10-06 |
| NCT ID | NCT02869802 |
| Official listing | https://clinicaltrials.gov/study/NCT02869802 |